Immix Biopharma (NASDAQ:IMMX – Get Free Report) had its price objective increased by research analysts at HC Wainwright from $25.00 to $27.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s target price indicates a potential upside of 244.39% from the company’s previous close.
Several other equities research analysts have also recently issued reports on the company. Morgan Stanley reiterated an “overweight” rating on shares of Immix Biopharma in a report on Tuesday, October 20th. Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a report on Wednesday, September 30th. Mizuho set a $23.00 target price on Immix Biopharma in a research report on Thursday, October 29th. Needham & Company LLC raised their target price on Immix Biopharma from $21.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, October 15th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.14.
View Our Latest Stock Analysis on IMMX
Immix Biopharma Price Performance
Shares of NASDAQ IMMX opened at $7.84 on Monday. The firm has a market cap of $560.87 million, a price-to-earnings ratio of -9.45 and a beta of 0.29. The company’s 50-day simple moving average is $9.82 and its 200-day simple moving average is $9.58. Immix Biopharma has a 52-week low of $3.56 and a 52-week high of $15.10.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). Equities research analysts anticipate that Immix Biopharma will post -0.76 EPS for the current fiscal year.
Hedge Funds Weigh In On Immix Biopharma
Institutional investors and hedge funds have recently bought and sold shares of the business. Blue Owl Capital Holdings LP purchased a new stake in Immix Biopharma during the 2nd quarter valued at about $4,511,000. Bank of America Corp DE acquired a new stake in Immix Biopharma in the 2nd quarter valued at about $4,260,000. Wellington Management Group LLP purchased a new position in Immix Biopharma in the 2nd quarter worth approximately $15,191,000. Tocqueville Asset Management L.P. purchased a new position in Immix Biopharma in the 2nd quarter worth approximately $913,000. Finally, Velan Capital Investment Management LP lifted its stake in Immix Biopharma by 46.6% in the 2nd quarter. Velan Capital Investment Management LP now owns 1,085,000 shares of the company’s stock worth $11,186,000 after purchasing an additional 345,000 shares in the last quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.
Immix Biopharma Company Profile
Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.
Featured Stories
- Five stocks we like better than Immix Biopharma
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
